Sos Lab

Who we are

Over the past decades the development of precision cancer medicine dramatically improved the overall survival of molecularly defined cancer patients, including highly aggressive lung cancer subtypes. However, the efficacy of virtually all therapies is limited through the inherent ability of individual tumor cells to cope with high cellular stress. At the same time a large number of tumors such as SCLC, remain poorly druggable despite our improved understanding of driver genes and critical survival programs. We are therefore committed to identify molecular nodes that are essential for tumor survival and exploit novel therapeutic concepts that could overcome current clinical challenges with a focus on lung cancer.

Our approach

To uncover the cellular networks that modify drug activity we employ systematic molecular profiling of transcriptional networks at high resolution, spatial resolution in combination with CRISPR-based genomic engineering and pharmacological perturbations including PROTACs-based methods. To capture the individual characteristics of lung cancer and other tumors we employ cellular models, organoids and genetically engineered mouse models. Moreover, we combine innovative molecular cell biology technologies with cutting-edge computational biology methods in order to make an impact on the development of novel cancer therapies.